Biology of Autism — Cascade Explained

Immune-derived autism does not have a single cause. It has a single convergent mechanistic node — the silencing of somatostatin-14 (SST-14) interneurons in the cortex, hippocampus, and hypothalamus — through which a wide range of initiating insults produce the same downstream outcome.

The initiating insults are diverse. No two children with immune-derived autism necessarily share the same combination of founding conditions. Yet a significant proportion share the same outcome, because all of these conditions — regardless of their origin — converge on the same series of intermediate mechanisms and arrive at the same point.

This convergence explains what has challenged autism researchers for decades. The phenotype appears heterogeneous from the outside because affected children entered the cascade at different points. The phenotype is consistent from the inside because all pathways converge on the same mechanistic node.

The cascade proceeds in recognisable layers: founding conditions elevate gut pH and disable digestion; incomplete protein digestion produces opioid peptide fragments that initiate two parallel downstream arms; a compromised gut barrier allows bacterial toxins into systemic circulation, activating immune pathways; those immune pathways silence SST-14 interneurons through both excitotoxic and transcriptional mechanisms; and silenced SST-14 interneurons disrupt the coordinated release of three neuropeptides — oxytocin, VIP, and secretin — producing the observable phenotype cluster.

Why gut pH is the upstream trigger

The cascade initiates when the gut environment shifts toward a higher-than-normal pH, disabling the enzymatic systems required for complete protein digestion. A wide range of independent conditions can produce this pH dysregulation — and in most affected individuals, several operate simultaneously.

The result is self-perpetuating: the pH elevation that initiates the cascade also generates conditions that maintain it, making resolution unlikely when only a single contributing factor is addressed.

Prenatal and perinatal initiating conditions

• Prenatal hormonal or immune disruption — exogenous hormones, maternal stress hormones, or maternal infection alter the development of acid-producing parietal cells before birth, reducing structural hydrochloric acid (HCl) production capacity from the start.
• Cesarean delivery — bypasses the birth canal microbial seeding event; hospital-acquired organisms including streptococcal species can establish dysbiotic colonization from the first days of life.
• Failure to establish nursing — breast milk oligosaccharides feed acid-producing commensal bacteria; colostrum shapes early gut immune tolerance; the sucking reflex activates motilin-driven motility. All are lost with formula dependence.
• Oral contraceptive nutritional depletion — pre-conception OCP use depletes B6, B12, folate, zinc, and magnesium. Zinc depletion is specifically consequential: zinc is the essential cofactor for carbonic anhydrase, which generates the hydrogen ions parietal cells use to produce HCl.
• Folate receptor antibodies — block methylfolate transport into the brain independently of dietary folate status, creating a dual methylation vulnerability when combined with cascade-driven adenosine accumulation.
• Genetic variants affecting acid production — proton pump gene polymorphisms, carbonic anhydrase variants, and zinc transporter variants reduce parietal cell acid output from birth. methylenetetrahydrofolate reductase (MTHFR) C677T compounds downstream methylation failure.

Environmental and toxic initiating conditions

• Glyphosate exposure — disrupts the shikimate pathway in bacteria, selectively depleting acid-producing commensals (Lactobacillus, Bifidobacterium) while sparing LPS-producing gram-negative species.
• Mercury and heavy metals — mercury binds directly to the CD26 receptor site on lymphocyte immune cells, blocking adenosine deaminase and initiating the adenosine accumulation that rate-limits the methionine synthase cycle.
• Organophosphate pesticides — inhibit acetylcholinesterase, producing muscarinic receptor downregulation over time and paradoxically reducing parietal cell acid responsiveness despite vagal overstimulation.
• Organophosphate flame retardants (OPFRs) — saturated polyurethane foam in infant sleep surfaces and car seats from 1975 to approximately 2015; detected in cord blood confirming prenatal exposure.
• Viral disruption of adenylyl cyclase — Bordetella pertussis toxin locks Gαi in inactive form; herpesviruses including CMV and EBV interact with G-protein regulatory components — independently impairing cAMP generation through the same pathway disrupted by adenosine accumulation.

Ongoing drivers that perpetuate pH dysregulation

• H. pylori infection — alkalinises the stomach by converting urea to ammonia, directly elevating gastric pH and damaging parietal cells through inflammatory mechanisms.
• Recurrent streptococcal infections — streptokinase blocks the CD26 receptor by occupying the adenosine deaminase binding site, continuously re-introducing the CD26-blocking mechanism and extending methylation suppression with each episode.
• Chronic sympathetic dominance and reduced vagal tone — in chronic stress states (persistent sensory overload, gut discomfort, immune activation), sustained sympathetic dominance suppresses vagal tone, reducing acetylcholine stimulation of parietal cells and chronically lowering acid output.
• Acetaminophen use — in young children with already-compromised sulphation capacity, acetaminophen metabolism depletes glutathione and compounds oxidative stress at the methylation failure step.
• Proton pump inhibitor therapy — prescribed for reflux in infants, PPIs directly suppress parietal cell acid production. When reflux reflects low motility and fermentation pressure rather than acid overproduction — as is common in this cascade — acid suppression deepens the underlying pH dysregulation while relieving the surface symptom.

Pepsin inactivation and the hidden malnutrition state

Pepsin is the primary gastric protease responsible for cleaving the proline bonds in casein and gluten proteins. It requires a pH of approximately 2.0 for optimal activity and becomes essentially inactive above pH 4.0. When founding conditions have elevated gastric pH above this threshold, pepsin cannot fulfill its digestive function regardless of dietary protein intake.

The intact proline-bonded peptide fragments that accumulate penetrate the intestinal mucosal wall — their rigid corkscrew geometry resists degradation by small intestinal proteases and allows entry into systemic circulation through the compromised barrier.

Three essential amino acids depend critically on pepsin-mediated proline bond cleavage for their release: phenylalanine, tyrosine, and tryptophan. When pepsin cannot cleave the proline bonds containing them, no amount of dietary protein corrects the resulting deficiency. The building blocks remain locked in undigested peptide fragments that pass through and are excreted rather than absorbed.

The result is hidden malnutrition — a child consuming an apparently adequate diet who is biochemically deficient in the three amino acid precursors from which dopamine, norepinephrine, serotonin, and melatonin are synthesized. This deficiency is not detectable by standard dietary assessment.

Intestinal barrier disruption and LPS translocation

The leaky gut initiated by proline-bonded peptide fragments penetrating the mucosal wall does not merely allow peptide fragments into systemic circulation. It creates a conduit through which gram-negative bacterial cell wall components — specifically lipopolysaccharide (LPS) — enter systemic circulation continuously.

LPS is one of the most potent known activators of the innate immune system. Even at nanogram concentrations it triggers pattern recognition receptor activation in macrophages and microglia, initiating production of IL-1β, IL-6, TNF-α, and IFN-γ. Microglial LPS activation is of particular consequence: activated microglia produce IL-1α, TNF-α, and complement component C1q — the three signals that drive the astrocyte A1 polarization shift described in the next section.

Chronic LPS translocation from a persistently compromised gut barrier is the primary upstream generator of the inflammatory cytokine environment that activates the two converging arms of SST-14 silencing that follow.

Arm 4A — IDO1 activation and excitotoxic pressure on SST-14 interneurons

The sustained elevation of IL-1β, IL-6, TNF-α, and IFN-γ activates indoleamine 2,3-dioxygenase 1 (IDO1) — an enzyme at a critical junction in tryptophan metabolism. IDO1 diverts tryptophan away from serotonin synthesis toward kynurenine and its downstream metabolites.

This creates the double tryptophan depletion: from above, pepsin inactivation prevents tryptophan release from dietary protein, reducing supply. From below, IDO1 continuously diverts available tryptophan into the kynurenine pathway, depleting what supply does reach circulation. Serotonin synthesis — which depends entirely on tryptophan as its sole dietary precursor — is simultaneously limited by impaired supply and active enzymatic diversion. The kynurenine-to-tryptophan (K:T) ratio in plasma is the direct quantitative measure of IDO1 activity. Launay et al. (2023, n=271) directly measured IDO1 activation, NAD⁺ levels, and plasma oxytocin in the same ASD cohort, establishing the downstream hypothalamic consequences as a measured human reality, not a theoretical one.

The kynurenine pathway bifurcates: one branch produces neuroprotective kynurenic acid; the other — driven by the same inflammatory cytokines activating IDO1 — produces quinolinic acid, a potent endogenous N-methyl-D-aspartate (NMDA) receptor agonist. Quinolinic acid's overstimulation of NMDA receptors forces calcium entry into neurons at rates exceeding their mitochondrial buffering capacity. SST-14 interneurons are disproportionately vulnerable: they maintain tonic high-frequency firing that demands continuous ATP production, making them particularly sensitive to mitochondrial energy depletion from calcium overload.

Further along the kynurenine pathway, quinolinic acid is converted to NAD⁺. Under chronic IDO1 activation, NAD⁺ consumption by mitochondrial stress response mechanisms exceeds the capacity of the pathway to replace it. The result is cellular NAD⁺ depletion that further compromises the mitochondrial ATP production on which SST-14 tonic firing depends — a self-reinforcing energy failure in the very neurons most vulnerable to the excitotoxic pressure driving it.

Arm 4B — NF-κB and direct transcriptional suppression of SST-14

In parallel with the IDO1 excitotoxic arm, the same inflammatory cytokines independently act on SST-14 interneurons through a transcriptional mechanism. Two named and distinct mechanisms operate simultaneously — and their simultaneous operation is what makes this suppression so difficult for the cell to overcome.

Mechanism A — NF-κB hijacks the transcriptional machinery. Pro-inflammatory cytokines activate NF-κB — nuclear factor kappa B. NF-κB enters the nucleus and competes directly with CREB (cAMP response element-binding protein) for CBP — CREB-binding protein — the co-activator both require to initiate gene transcription. CBP is present in limited quantities and cannot be rapidly upregulated. Under chronic inflammatory conditions, NF-κB dominates this competition, redirecting CBP away from SST-14 gene expression and toward the inflammatory transcriptional program. CREB is left at the somatostatin gene's cyclic AMP response element (CRE, established by Montminy et al., PNAS 1986) without the co-activator it needs. Simultaneously, NF-κB recruits HDAC enzymes to the chromatin surrounding the somatostatin gene promoter — removing acetyl groups from histones, tightening DNA winding, and making the CRE physically less accessible.

Mechanism B — Adenosine starvation of the cAMP signal. CREB requires phosphorylation by PKA to become active. PKA is activated by cAMP. cAMP is produced by adenylyl cyclase. Adenosine accumulated through the CD26 blockade of Arm 2B activates inhibitory Gαi-coupled adenosine receptors on SST-14 interneurons, suppressing adenylyl cyclase. Less adenylyl cyclase means less cAMP, less PKA activation, and less CREB phosphorylation — independently of Mechanism A. The somatostatin gene's CRE is deprived of its activating signal from an entirely different direction simultaneously. This is also the mechanism described in full in Doc 04 — When the Signal Cannot Get Through.

Why both simultaneously is worse than either alone. Mechanism A suppresses CREB even when cAMP is present — by taking away CBP and compacting the chromatin. Mechanism B prevents cAMP from activating CREB in the first place. Neither alone forecloses all compensatory routes. Both together do. The interneuron's structural and metabolic machinery remains largely intact — its gene expression has been turned down from two independent directions. Remove both mechanisms and CREB can resume driving SST-14 expression. This is the mechanistic basis for the clinical response to immunoglobulin therapy in State 1 patients.

Two additional mechanisms compound the transcriptional suppression simultaneously:

• Autoantibody-mediated functional silencing — the chronically activated adaptive immune system produces autoantibodies against neural surface proteins on SST-14 interneurons, impairing membrane signal transduction even when some SST-14 peptide production is maintained.
• Estrogen compensatory axis — the Gq-mER estrogen pathway (Qiu et al., J Neuroscience 2003) generates cAMP through a Gαq-mediated route entirely independent of the Gαi adenosine suppression — bypassing Mechanism B but not Mechanism A. This partial back-door compensation explains why females with equivalent cascade burden retain more SST-14 output than prepubertal males. See the estrogen-cAMP section in Neuropeptide Cascade Disruption below.

The A1 astrocyte shift and loss of neural plasticity

Microglial activation driven by persistent LPS translocation and SST-14 loss of anti-inflammatory output produces IL-1α, TNF-α, and complement component C1q — the three signals that drive astrocyte polarization toward the A1 reactive phenotype (Liddelow et al., Nature 2017).

A2 astrocytes support synaptogenesis, produce brain-derived neurotrophic factor (BDNF) and the synaptogenic proteins hevin and SPARCL1 that drive thalamocortical connectivity, and promote synaptic pruning accuracy. A1 reactive astrocytes suppress synaptogenesis, reduce BDNF production, withdraw hevin and SPARCL1, and impair glutamate clearance from the synaptic cleft — compounding excitotoxic pressure.

Critically, the A1/A2 transition is not permanent. Liddelow et al. established that the A1 reactive state is maintained by ongoing microglial signaling and reverses when those signals are removed. Neural plasticity — the cellular substrate for learning, social development, and behavioral flexibility — can be restored by interventions that reduce microglial A1-inducing activation. This directly challenges the clinical assumption that the adult brain's developmental window is irreversibly closed.

Oxytocin — loss of coordinated social salience signaling

SST-14 interneurons in the paraventricular nucleus modulate the timing and amplitude of oxytocin release in response to social and safety signals. When SST-14 interneuron output is suppressed, oxytocin release becomes blunted, irregular, and uncoupled from social context.

The clinical consequence is not the absence of social capacity but the absence of the neurochemical signal that makes social interaction feel rewarding and worth seeking — a motivational deficit at the neurochemical level rather than a cognitive or structural one.

This framing explains the consistent failure of exogenous oxytocin as a treatment for ASD. The definitive null result was established by the SOARS-B trial (Sikich et al., NEJM 2021, n=290) and confirmed by meta-analysis. Exogenous oxytocin cannot restore the circuit timing, pulsatility, and social-contextual coupling that SST-14 interneuron coordination normally provides. Restoration requires addressing the upstream SST-14 silencing — not replacing the downstream output.

VIP — G-protein cascade failure across four biological systems

Vasoactive intestinal peptide (VIP) signaling operates through the canonical G-protein cascade: receptor → Gαs → adenylyl cyclase → cAMP → PKA → CREB. In the cascade established by the preceding sections, this chain has been disrupted at three independent points simultaneously:

• Adenosine accumulation from CD26 blockade activates Gi-coupled adenosine receptors that suppress adenylyl cyclase
• SST-14 silencing removes the coordinating inhibitory tone that allows VIP-driven cAMP activity to be contextually regulated
• Cytokine-driven NF-κB directly suppresses CREB at the transcriptional endpoint of the pathway

VIP signaling fails not because VIP is absent but because the intracellular cascade through which it acts has been disrupted at three independent mechanistic points. The four systems simultaneously disrupted by VIP loss are:

• Circadian clock — VIP is the primary neuropeptide synchronizing the suprachiasmatic nucleus; its loss produces the fragmented, arrhythmic sleep characteristic of ASD as a loss of circadian synchronization at the cellular oscillator level
• Sensory processing — VIP-driven disinhibition provides context-appropriate sensory gain control in cortical interneuron networks; its loss produces modality-nonspecific sensory processing abnormalities
• Gut motility — VIP drives smooth muscle relaxation in peristalsis; its loss produces slow transit, constipation, and irregular motility
• Immune regulation — VIP suppresses pro-inflammatory cytokine production; its loss removes an anti-inflammatory brake at the moment the inflammatory cascade most requires regulation

The estrogen-cAMP-CREB-SST14 axis — why four to one male predominance

A partial compensatory mechanism for the adenylyl cyclase suppression affecting VIP signaling and SST-14 expression exists in females and is absent in prepubertal males. Estradiol activates adenylyl cyclase through a non-classical membrane-initiated pathway: membrane-associated estrogen receptor alpha couples to Gαq, activates protein kinase C, upregulates adenylyl cyclase VII, and generates cAMP independently of the Gi-mediated adenosine suppression that is reducing cAMP through the conventional receptor pathway (Aronica et al., PNAS 1994).

Because the somatostatin gene contains a cAMP response element (Montminy et al., PNAS 1986), this estradiol-generated cAMP drives SST-14 gene transcription through CREB — providing a partially compensatory transcriptional activation that counteracts the NF-κB-mediated CREB suppression operating simultaneously. A female carrying equivalent upstream cascade burden retains a degree of SST-14 expression through this route that a prepubertal male with identical biology cannot access.

At puberty, testosterone-to-estradiol conversion through brain aromatase provides prepubertal males with their first access to this compensatory pathway — accounting for the spontaneous improvement in social, communicative, and behavioral function that families frequently report at puberty in male autistic children.

Secretin — compound failure from above and below

Secretin faces disruption from two independent directions. From below: gut pH dysregulation prevents duodenal chyme from reaching the pH 4.2 threshold required for S-cell secretin release; gut SST-28 overactivation provides a second suppressive layer through paracrine D-cell signaling. From above: SST-14 silencing removes the central neural coordination that secretin signaling requires for its brain-side effects in the cerebellum, hippocampus, and hypothalamus.

The secretin trial history illustrates this compound failure — and simultaneously provides the earliest proof-of-concept that recovery in immune-derived autism is possible. Horvath et al. (1998) reported behavioral improvements in three autistic children receiving intravenous secretin during endoscopy. The improvements were real: intravenous delivery bypassed the blocked S-cell pH-dependent release mechanism entirely, delivering secretin directly to a genuinely secretin-deficient circuit. Subsequent unselected population trials (Sandler 1999, Owley 2001, Cochrane review 2012, 14 null RCTs) confirmed no consistent benefit — not because the mechanism is wrong, but because the unselected enrollment diluted the responsive subgroup to statistical insignificance. The same population-selection failure explains the null results from unselected IVIG and oxytocin trials.

Thalamic gating failure — a second mechanism for sensory dysregulation

Beyond cortical VIP-driven gain control failure, SST-14 interneuron silencing in the thalamic reticular nucleus (TRN) provides a second and anatomically upstream mechanism for sensory processing abnormalities. The TRN is a shell of inhibitory interneurons expressing SST-14 that surrounds the thalamus and gates the flow of sensory information from thalamic relay nuclei to primary sensory cortices. All sensory modalities except olfaction pass through this thalamic gateway.

When TRN SST-14 interneurons are silenced, the thalamic gate is held open continuously. Sensory signals that should be attenuated at the thalamic relay level arrive at primary sensory cortex with their full amplitude intact — where they then encounter cortical processing networks that have also lost VIP-driven dynamic gain control. The two-level sensory filtering failure in series — thalamic gating disruption plus cortical gain control disruption — explains both the severity and the modality-nonspecific nature of sensory processing abnormalities: all sensory modalities are simultaneously affected because the disruption is upstream of the modality-specific cortical processing areas.

The clinical features of immune-derived autism are not a collection of independently caused characteristics. They are simultaneous downstream expressions of a unified upstream mechanism, organized by the neuropeptide system whose loss produces each domain of impairment.

Treating each domain as an independent problem requiring its own specialist and intervention addresses the observable consequences without engaging the upstream failure that produces all of them. This is why a child with immune-derived autism characteristically carries multiple specialist diagnoses — GI physician, sleep specialist, occupational therapist, speech therapist — none of which resolves the biological source.

Regressive autism and PANS/PANDAS — temporal expressions of the same cascade

Regressive autism — skill loss between 18 and 36 months in a child with apparently normal early development — is not a mechanistically distinct subtype. It is a temporal expression of the cascade under threshold dynamics. Compensatory mechanisms may maintain adequate SST-14 interneuron output during early development while cascade burden accumulates. A second biological challenge — febrile illness, streptococcal infection producing acute IDO1 activation, dietary change increasing opioid peptide load — crosses the threshold at which SST-14 interneurons can no longer maintain coordinating output. The regression is the moment the threshold was crossed, not the moment pathology began.

PANS and its streptococcal-associated variant PANDAS represent the accelerated acute expression of the same cascade. Streptococcal molecular mimicry drives rapid autoantibody production against neural surface proteins on SST-14 interneurons and basal ganglia neurons, producing the sudden-onset neuropsychiatric presentation characteristic of these conditions.

ADHD and AuDHD — regional variants of SST-14 silencing

The convergent cascade extends beyond ASD to the broader neurodevelopmental spectrum. ADHD involves dopamine signaling insufficiency in the prefrontal cortex, norepinephrine dysregulation, and impaired inhibitory control from reduced GABAergic interneuron tone — all mechanistically produced by the same cascade. Phenylalanine and tyrosine deficiency from pepsin inactivation depletes dopaminergic precursors. SAMe depletion from methylation failure impairs COMT-mediated catecholamine regulation. Prefrontal SST-14 interneuron silencing reduces the inhibitory tone on which executive function and attentional control depend.

The clinical distinction between ASD and ADHD — and the high co-occurrence that produces the AuDHD combined presentation — may reflect the regional distribution of SST-14 silencing: predominant prefrontal silencing produces ADHD-predominant features; predominant hypothalamic, amygdala, and sensory cortex silencing produces ASD-predominant features; extensive silencing across both regions produces the combined AuDHD presentation.